11C-ACETATE ( DrugBank: Acetate, 11C-ACETATE )

4 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	1
13	Multiple sclerosis/Neuromyelitis optica	1
86	Pulmonary arterial hypertension	1
88	Chronic thromboembolic pulmonary hypertension	1

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01143454 (ClinicalTrials.gov)	July 21, 2010	11/6/2010	Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System	Cardiovascular Disease Discovery Protocol	Cardiomyopathy;Li-Fraumeni Syndrome;Parkinson's Disease;Atherosclerosis;Cardiovascular Capacity	Drug: 11C-Acetate;Drug: 13N-Amonia	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Recruiting	1 Year	100 Years	All	5000		United States

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000018154	2015/07/01	01/07/2015	11C-acetate PET for Multiple sclerosis	11C-acetate PET for Multiple sclerosis - 11C-acetate PET for Multiple sclerosis	Multiple Sclerosis, NMO	Withdraw blood before and after the injection of 11C-acetate	department of neurology, Osaka university school of medicine	NULL	Recruiting	20years-old	75years-old	Male and Female	30	Not applicable	Japan

Clinical trials : 1,205 / Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01953965 (ClinicalTrials.gov)	September 2013	26/9/2013	Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.	11C-acetate/18Fluorodeoxyglucose-FDG PET/Cardiac MRI in Pulmonary Hypertension	Pulmonary Arterial Hypertension;Chronic Thromboembolic Pulmonary Hypertension	Drug: 11C-acetate;Drug: [18F]Fluoro-2-deoxy-2-D-glucose;Drug: MultiHance	Brigham and Women's Hospital	University of Pennsylvania;University of Maryland;Yale University	Terminated	18 Years	72 Years	Both	4	Phase 2	United States

Clinical trials : 157 / Drugs : 107 - (DrugBank : 22) / Drug target genes : 14 - Drug target pathways : 54

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01953965 (ClinicalTrials.gov)	September 2013	26/9/2013	Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.	11C-acetate/18Fluorodeoxyglucose-FDG PET/Cardiac MRI in Pulmonary Hypertension	Pulmonary Arterial Hypertension;Chronic Thromboembolic Pulmonary Hypertension	Drug: 11C-acetate;Drug: [18F]Fluoro-2-deoxy-2-D-glucose;Drug: MultiHance	Brigham and Women's Hospital	University of Pennsylvania;University of Maryland;Yale University	Terminated	18 Years	72 Years	Both	4	Phase 2	United States